2型糖尿病的發(fā)生率在全球范圍內(nèi)呈逐年增高趨勢，已成為威脅人們健康和生命的非傳染性疾病。埃格列凈（Ertugliflozin，Steglatro^®）是鈉-葡萄糖共轉(zhuǎn)運(yùn)蛋白2抑制劑，由美國輝瑞公司和德國默克公司合作研發(fā)，于2018年3月被美國FDA批準(zhǔn)用于改善2型糖尿病成年患者的血糖控制，可單藥治療或與其他降血糖藥物聯(lián)合使用。對埃格列凈的基本信息、藥理學(xué)、用藥注意事項(xiàng)和臨床試驗(yàn)等進(jìn)行介紹。

The incidence rate of type 2 diabetes mellitus (T2DM) increased year by year in the worldwide has become a non communicable disease that threatens human health and life. Ertugliflozin (Steglatro^TM) is an orally sodium glucose co-transporter 2 inhibitor developed by Merck and Pfizer Pharmaceuticals Ltd as a treatment for T2DM. In March 2018, the novel drug has recently been approved by the US FDA as an adjunct to diet and exercises to improve glycaemic control in adults with T2DM as either monotherapy or in combination with other hypoglycemic agents. The base information, pharmacology, clinical evaluation and safety of empagliflozin were reviewed in this article.